Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Mar;12(3):159-164.
doi: 10.21037/jtd.2020.01.65.

Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion

Yuyan Zheng  1 , Min Zhou  2 , Surein Arulananda  3 , Sang-Won Um  4 , Hecheng Li  1
Affiliations
Case Reports

Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion

Yuyan Zheng et al. J Thorac Dis. 2020 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: HL serves as the unpaid editorial board member of Journal of Thoracic Disease from Jul 2018 to Jun 2020. S Arulananda declares personal fees from Merck-Sharpe Dohme, Astra Zeneca, Boehringer-Ingelheim and Roche. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Axial diffusion-weighted (A) and T2W FLAIR (B) brain magnetic resonance imaging on January 23, 2017, showing a new-found brain metastasis in the left temporal lobe.
Figure 2
Figure 2
Axial diffusion-weighted (A), T2W FLAIR (B), and contrast-enhanced (C) brain magnetic resonance imaging on December 09, 2018. The metastasis in the left temporal lobe enlarged during gefitinib treatment.
Figure 3
Figure 3
Axial diffusion-weighted (A), T2W FLAIR (B), and contrast-enhanced (C) brain magnetic resonance imaging on February 13, 2019. The metastasis in the left temporal lobe slightly regressed after about one month of anlotinib treatment.
See this image and copyright information in PMC

Comment in

References

    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Ma Y, Xin S, Lin Q, et al. The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Ann Transl Med 2019;7:806. 10.21037/atm.2019.12.60 - DOI - PMC - PubMed
    1. Yoshida K, Kanda S, Shiraishi H, et al. Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study. J Thorac Dis 2019;11:1347-54. 10.21037/jtd.2019.03.61 - DOI - PMC - PubMed
    1. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7. 10.1158/1078-0432.CCR-12-2246 - DOI - PMC - PubMed
    1. Lettig L, Sahnane N, Pepe F, et al. EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. Transl Lung Cancer Res 2019;8:584-92. 10.21037/tlcr.2019.09.18 - DOI - PMC - PubMed

Publication types